Search

Displaying results 3581 - 3590 of 5451 in total
  1. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated … [A260651] Therefore, quizartinib is proven to be a beneficial addition to the current AML treatment regimen, although serious side effects such as QT prolongation necessitates further research to optimize

  2. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen

    go.drugbank.com/drugs/DB10284
    ApprovedInvestigational

    It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily

  3. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    [A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes.

  4. Drug

    Triclocarban

    go.drugbank.com/drugs/DB11155
    Approved

    It is a bacteriostatic compound that has been found in antibacterial soaps and other personal care products.

    Products: a.c.care Bees Troubled Skin Care 2 pcs Set, a.c.care Bees Foam Cleanser Troubled Skin Care 2 pcs Set
  5. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns.

  6. Drug

    Licofelone

    go.drugbank.com/drugs/DB04725
    Experimental

    It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis. … Although phase III trials have been successfully completed in OA patients no dates for regulatory submission have yet been given.

  7. Drug

    Typhoid Vi polysaccharide vaccine

    go.drugbank.com/drugs/DB10803
    ApprovedInvestigational

    It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older.

    Products: TYPHIM VI INJECTION 0.025 mg/0.5 ml
  8. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen

    go.drugbank.com/drugs/DB10285
    ApprovedInvestigational

    It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily

  9. Drug

    GS-441524

    go.drugbank.com/drugs/DB15686
    Investigational

    [L13775] _In vitro_ studies of GS-441524 have determined it has a higher EC<sub>50</sub> than remdesivir against a number of viruses, meaning GS-441524 is less potent.

  10. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions.

    Synonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER, IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER